Loading…

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Background Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for se...

Full description

Saved in:
Bibliographic Details
Published in:The journal of prevention of Alzheimer's disease 2022, Vol.9 (4), p.780-790
Main Authors: Wischik, Claude M., Bentham, P., Gauthier, S., Miller, S., Kook, K., Schelter, B. O.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c359t-1c47f056c27777cc64922842896e3e0d6088a9526eff294218a3ae2211bb0623
container_end_page 790
container_issue 4
container_start_page 780
container_title The journal of prevention of Alzheimer's disease
container_volume 9
creator Wischik, Claude M.
Bentham, P.
Gauthier, S.
Miller, S.
Kook, K.
Schelter, B. O.
description Background Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for selection of 16 mg/day as monotherapy as the optimal treatment regime and the design rationale of a confirmatory Phase 3 trial (LUCIDITY). Design The trial comprises a 12-month double-blind, placebo-controlled phase followed by a 12-month modified delayed-start open-label treatment phase. Setting 76 clinical research sites in North America and Europe. Participants 545 patients with probable AD or MCI-AD in the final version of the protocol. Intervention Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase. All participants in the open-label phase receive the 16 mg/day dose. Measurements Co-primary clinical outcomes are the 11-item Alzheimer’s Disease Assessment Scale (ADAS-cog 11 ) and the 23-item Alzheimer’s Disease Cooperative Study — Activities of Daily Living (ADCS-ADL 23 ). Secondary biomarker measures include whole-brain atrophy and temporal lobe 18 F-fluorodeoxyglucose positron emission tomography. Results 446 participants are expected to complete the 12-month placebo-controlled phase in March 2022. Conclusions If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. As low-dose oral hydromethylthionine mesylate is simple to use clinically, does not cause amyloid-related imaging abnormalities and has a benign safety profile, it would likely improve AD management.
doi_str_mv 10.14283/jpad.2022.63
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9226274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2728467860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-1c47f056c27777cc64922842896e3e0d6088a9526eff294218a3ae2211bb0623</originalsourceid><addsrcrecordid>eNpVkc1u1DAUhSMEElXpkv1dsmim_sk4CQukYQZopaJWMHvLcW4Sjxx7sBOkdMVr8Ey8BU-CO-0GS5Yt3Xs-n-uTZW8pWdGCVfzqcFTtihHGVoK_yM5YwUROmBAv052VRb6uSPk6u4jxQAihNRW8rs6yP3dBWdirGTZ9H7BXk_EObtxgGjP5AF3aG_swoBkx_P31O8LORFQR38MOo-ndJdwHn5QxgnItfFTRxJPqO1rUJ5rvYBoQqICxv2rVAjsfEYwDBfdDQgG_hG9J7EfzgG0CWqWx8fnWuyl4a7GFfTDJZgJdL23wI07DYqchwY1D-IpxsWrCN9mrTtmIF8_nebb__Gm_vc5v777cbDe3uebresqpLsqOrIVmZVpai6JmrEp_WAvkSFpBqkrVayaw61hdMFoprpAxSpuGCMbPsw9P2OPcjNhqTC6VlcdgRhUW6ZWR_1ecGWTvf8r0jEhJJMC7Z0DwP2aMkxxN1GitcujnKFmZ7IiyEiS1rp5aY8K7HoM8-Dm4NJ2kRJ6Cl4_By8fgpeD8H_yepPM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728467860</pqid></control><display><type>article</type><title>Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate</title><source>Springer Nature</source><creator>Wischik, Claude M. ; Bentham, P. ; Gauthier, S. ; Miller, S. ; Kook, K. ; Schelter, B. O.</creator><creatorcontrib>Wischik, Claude M. ; Bentham, P. ; Gauthier, S. ; Miller, S. ; Kook, K. ; Schelter, B. O.</creatorcontrib><description>Background Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for selection of 16 mg/day as monotherapy as the optimal treatment regime and the design rationale of a confirmatory Phase 3 trial (LUCIDITY). Design The trial comprises a 12-month double-blind, placebo-controlled phase followed by a 12-month modified delayed-start open-label treatment phase. Setting 76 clinical research sites in North America and Europe. Participants 545 patients with probable AD or MCI-AD in the final version of the protocol. Intervention Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase. All participants in the open-label phase receive the 16 mg/day dose. Measurements Co-primary clinical outcomes are the 11-item Alzheimer’s Disease Assessment Scale (ADAS-cog 11 ) and the 23-item Alzheimer’s Disease Cooperative Study — Activities of Daily Living (ADCS-ADL 23 ). Secondary biomarker measures include whole-brain atrophy and temporal lobe 18 F-fluorodeoxyglucose positron emission tomography. Results 446 participants are expected to complete the 12-month placebo-controlled phase in March 2022. Conclusions If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. As low-dose oral hydromethylthionine mesylate is simple to use clinically, does not cause amyloid-related imaging abnormalities and has a benign safety profile, it would likely improve AD management.</description><identifier>ISSN: 2274-5807</identifier><identifier>EISSN: 2426-0266</identifier><identifier>DOI: 10.14283/jpad.2022.63</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Geriatrics/Gerontology ; Medicine ; Medicine &amp; Public Health ; Neurology ; Original Research</subject><ispartof>The journal of prevention of Alzheimer's disease, 2022, Vol.9 (4), p.780-790</ispartof><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c359t-1c47f056c27777cc64922842896e3e0d6088a9526eff294218a3ae2211bb0623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Wischik, Claude M.</creatorcontrib><creatorcontrib>Bentham, P.</creatorcontrib><creatorcontrib>Gauthier, S.</creatorcontrib><creatorcontrib>Miller, S.</creatorcontrib><creatorcontrib>Kook, K.</creatorcontrib><creatorcontrib>Schelter, B. O.</creatorcontrib><title>Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate</title><title>The journal of prevention of Alzheimer's disease</title><addtitle>J Prev Alzheimers Dis</addtitle><description>Background Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for selection of 16 mg/day as monotherapy as the optimal treatment regime and the design rationale of a confirmatory Phase 3 trial (LUCIDITY). Design The trial comprises a 12-month double-blind, placebo-controlled phase followed by a 12-month modified delayed-start open-label treatment phase. Setting 76 clinical research sites in North America and Europe. Participants 545 patients with probable AD or MCI-AD in the final version of the protocol. Intervention Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase. All participants in the open-label phase receive the 16 mg/day dose. Measurements Co-primary clinical outcomes are the 11-item Alzheimer’s Disease Assessment Scale (ADAS-cog 11 ) and the 23-item Alzheimer’s Disease Cooperative Study — Activities of Daily Living (ADCS-ADL 23 ). Secondary biomarker measures include whole-brain atrophy and temporal lobe 18 F-fluorodeoxyglucose positron emission tomography. Results 446 participants are expected to complete the 12-month placebo-controlled phase in March 2022. Conclusions If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. As low-dose oral hydromethylthionine mesylate is simple to use clinically, does not cause amyloid-related imaging abnormalities and has a benign safety profile, it would likely improve AD management.</description><subject>Geriatrics/Gerontology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neurology</subject><subject>Original Research</subject><issn>2274-5807</issn><issn>2426-0266</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkc1u1DAUhSMEElXpkv1dsmim_sk4CQukYQZopaJWMHvLcW4Sjxx7sBOkdMVr8Ey8BU-CO-0GS5Yt3Xs-n-uTZW8pWdGCVfzqcFTtihHGVoK_yM5YwUROmBAv052VRb6uSPk6u4jxQAihNRW8rs6yP3dBWdirGTZ9H7BXk_EObtxgGjP5AF3aG_swoBkx_P31O8LORFQR38MOo-ndJdwHn5QxgnItfFTRxJPqO1rUJ5rvYBoQqICxv2rVAjsfEYwDBfdDQgG_hG9J7EfzgG0CWqWx8fnWuyl4a7GFfTDJZgJdL23wI07DYqchwY1D-IpxsWrCN9mrTtmIF8_nebb__Gm_vc5v777cbDe3uebresqpLsqOrIVmZVpai6JmrEp_WAvkSFpBqkrVayaw61hdMFoprpAxSpuGCMbPsw9P2OPcjNhqTC6VlcdgRhUW6ZWR_1ecGWTvf8r0jEhJJMC7Z0DwP2aMkxxN1GitcujnKFmZ7IiyEiS1rp5aY8K7HoM8-Dm4NJ2kRJ6Cl4_By8fgpeD8H_yepPM</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Wischik, Claude M.</creator><creator>Bentham, P.</creator><creator>Gauthier, S.</creator><creator>Miller, S.</creator><creator>Kook, K.</creator><creator>Schelter, B. O.</creator><general>Springer International Publishing</general><scope>C6C</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2022</creationdate><title>Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate</title><author>Wischik, Claude M. ; Bentham, P. ; Gauthier, S. ; Miller, S. ; Kook, K. ; Schelter, B. O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-1c47f056c27777cc64922842896e3e0d6088a9526eff294218a3ae2211bb0623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Geriatrics/Gerontology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neurology</topic><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wischik, Claude M.</creatorcontrib><creatorcontrib>Bentham, P.</creatorcontrib><creatorcontrib>Gauthier, S.</creatorcontrib><creatorcontrib>Miller, S.</creatorcontrib><creatorcontrib>Kook, K.</creatorcontrib><creatorcontrib>Schelter, B. O.</creatorcontrib><collection>SpringerOpen</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of prevention of Alzheimer's disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wischik, Claude M.</au><au>Bentham, P.</au><au>Gauthier, S.</au><au>Miller, S.</au><au>Kook, K.</au><au>Schelter, B. O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate</atitle><jtitle>The journal of prevention of Alzheimer's disease</jtitle><stitle>J Prev Alzheimers Dis</stitle><date>2022</date><risdate>2022</risdate><volume>9</volume><issue>4</issue><spage>780</spage><epage>790</epage><pages>780-790</pages><issn>2274-5807</issn><eissn>2426-0266</eissn><abstract>Background Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for selection of 16 mg/day as monotherapy as the optimal treatment regime and the design rationale of a confirmatory Phase 3 trial (LUCIDITY). Design The trial comprises a 12-month double-blind, placebo-controlled phase followed by a 12-month modified delayed-start open-label treatment phase. Setting 76 clinical research sites in North America and Europe. Participants 545 patients with probable AD or MCI-AD in the final version of the protocol. Intervention Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase. All participants in the open-label phase receive the 16 mg/day dose. Measurements Co-primary clinical outcomes are the 11-item Alzheimer’s Disease Assessment Scale (ADAS-cog 11 ) and the 23-item Alzheimer’s Disease Cooperative Study — Activities of Daily Living (ADCS-ADL 23 ). Secondary biomarker measures include whole-brain atrophy and temporal lobe 18 F-fluorodeoxyglucose positron emission tomography. Results 446 participants are expected to complete the 12-month placebo-controlled phase in March 2022. Conclusions If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. As low-dose oral hydromethylthionine mesylate is simple to use clinically, does not cause amyloid-related imaging abnormalities and has a benign safety profile, it would likely improve AD management.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.14283/jpad.2022.63</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2274-5807
ispartof The journal of prevention of Alzheimer's disease, 2022, Vol.9 (4), p.780-790
issn 2274-5807
2426-0266
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9226274
source Springer Nature
subjects Geriatrics/Gerontology
Medicine
Medicine & Public Health
Neurology
Original Research
title Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A17%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Tau%20Aggregation%20Inhibitor%20for%20Alzheimer%E2%80%99s%20Disease:%20Design,%20Progress%20and%20Basis%20for%20Selection%20of%20the%2016%20mg/day%20Dose%20in%20a%20Phase%203,%20Randomized,%20Placebo-Controlled%20Trial%20of%20Hydromethylthionine%20Mesylate&rft.jtitle=The%20journal%20of%20prevention%20of%20Alzheimer's%20disease&rft.au=Wischik,%20Claude%20M.&rft.date=2022&rft.volume=9&rft.issue=4&rft.spage=780&rft.epage=790&rft.pages=780-790&rft.issn=2274-5807&rft.eissn=2426-0266&rft_id=info:doi/10.14283/jpad.2022.63&rft_dat=%3Cproquest_pubme%3E2728467860%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c359t-1c47f056c27777cc64922842896e3e0d6088a9526eff294218a3ae2211bb0623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2728467860&rft_id=info:pmid/&rfr_iscdi=true